 - Participation in any other investigational study in which receipt of investigational drug or device occurred within 6 months before screening for this study. Prior treatment with PTH-like drugs whether commercially available or through participation in an investigational study, including PTH 1-84, PTH 1-34, or other N-terminal fragments or analogs of PTH or PTH-related protein, within 3 months before screening. 